Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 4/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.32 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29136131 | 0.86 | RIPK1 (0.49) | RIPK1SLC18A3BACE1 | |
| SCHEMBL16634470 | 0.85 | DRD2 (0.40) | RIPK1SLC18A3BACE1 | |
| SCHEMBL28059312 | 0.81 | LMNA (0.43) | — | |
| SCHEMBL3988014 | 0.81 | HDAC6 (0.34) | RIPK1OPRM1OPRD1 | |
| SCHEMBL27224984 | 0.81 | HDAC6 (0.34) | RIPK1 | |
| SCHEMBL20448611 | 0.80 | TRPC6 (0.40) | RIPK1DDB1CRBN | |
| SCHEMBL3502629 | 0.79 | QDPR (0.42) | — | |
| SCHEMBL28053867 | 0.79 | OPRK1 (0.41) | OPRM1 | |
| SCHEMBL28053930 | 0.79 | ALDH1A1 (0.39) | OPRM1OPRD1DDB1CRBN | |
| SCHEMBL4615095 | 0.77 | NPC1 (0.45) | BACE1KMOPARP10PARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105384695-A | Pyrimidine derivative, preparation method therefor and application thereof in medicine | SICHUAN HAISCO PHARMACEUTICAL CO LTD | 2016-03-09 | — | — | CN | disclosed |
| US-7473698-B2 | Secondary amino anilinic piperidines as MCH1 antagonists and uses thereof | H. LUNBECK A/S (DK) | 2009-01-06 | — | — | US | disclosed |
| EP-1556351-A4 | SECONDARY AMINO ANILINIC PIPERIDINES AS MCH1 ANTAGONISTS AND USES THEREOF | LUNDBECK & CO AS H (DK) | 2007-07-25 | — | — | EP | disclosed |
| US-20050245743-A1 | Secondary amino anilinic piperidines as mch1 antagonists and uses thereof | H. LUNDBECK A/S (DK) | 2005-11-03 | — | — | US | disclosed |
| EP-1556351-A1 | SECONDARY AMINO ANILINIC PIPERIDINES AS MCH1 ANTAGONISTS AND USES THEREOF | H. Lundbeck A/S (DK) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004005257-A1 | SECONDARY AMINO ANILINIC PIPERIDINES AS MCH1 ANTAGONISTS AND USES THEREOF | H. LUNDBECK A/S (DK) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245743-A1 | Secondary amino anilinic piperidines as mch1 antagonists and uses thereof | MCHR1, MCHR2, MC1R | RIPK1 4666/4885OPRM1 46/4885OPRD1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.